Vital3D Technologies
Vital3D Technologies develops a precision laser bioprinting platform (FemtoBrush) for medical devices, therapeutics and regenerative medicine, with lead programs in vascular stents and 3D cell culture systems.
- CEO / Founder
- Vidmantas Sakalys
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $2.2M
- Latest Round
- Seed
- Key Investors
- Private Lithuanian businesses
Technology & Products
Key Products
["Perfectly Fitted Stents (lead program - validated in animal trials)","3D Cell Culture Systems (validated in vitro)","Implantable Grafts (prototype)","Wound Patches (early development)","Microfluidics (prototype)","3D bioprinted human organs (long-term goal)"]
Technological Advantage
Proprietary bioprinting technology combined with a phased go-to-market strategy starting in the veterinary sector to build proof-of-concept and drive revenue.
Differentiation
Value Proposition
For pets: accelerates wound healing and reduces treatment costs. For humans: addresses organ shortages and improves drug development through bioprinted tissues.
How They Differentiate
Focused initial entry into the veterinary wound care market with a validated product, reducing market risk before expanding to human applications.
Market & Competition
Target Customers
Veterinary clinics, pet owners; planned expansion to hospitals and healthcare providers.
Industry Verticals
["Veterinary Medicine","Human Healthcare","Regenerative Medicine","Drug Discovery","Medical Devices"]
Competitors
Organovo Holdings Inc.; Poietis SA; Other emerging bioprinting companies
Growth & Milestones
Growth Metrics
Serviceable addressable market for pet wound care estimated at €76.5 million in the EU and US; planning to sell 100,000 units by 2027–2028.
Major Milestones
["Development of VitalHeal bioprinted wound patch for pets","Scheduled clinical tests in Lithuania and the UK","Planned release of a non-degradable pet patch next year","Collaboration with Lithuania's National Cancer Institute"]
Notable Customers
null